The National Institutes of Health (NIH) has released a funding opportunity under the number RFA-CA-24-015, titled “Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional).” This grant, falling under the discretionary category, is aimed at propelling cancer detection and diagnosis research forward (CFDA Number: 93.394). With an award ceiling of $150,000, this initiative seeks to encourage revision applications from currently funded NCI P30 centers to integrate new technical approaches or instruments developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program into their existing research projects.
The main goal of this Notice of Funding Opportunity (NOFO) is to expand upon original research questions or accelerate progress in ongoing studies by incorporating cutting-edge technology from the NCI IMAT program. The awards from this NOFO are designed to incentivize independent validation and enhance the adoption of these emerging technologies by appropriate research communities. This initiative underscores the NCI’s commitment to fostering interdisciplinary collaboration in the development of innovative tools and methods that not only enable in-depth cancer research but also quicken the pace of scientific discovery. By facilitating the integration of novel NCI-supported technologies into existing cancer research projects, this grant opportunity represents a significant step towards accelerating advancements in cancer detection, diagnosis, and treatment. The NIH’s investment in this area reflects an ongoing effort to drive innovation and collaboration in cancer research, aiming to improve patient outcomes and expand the frontiers of our understanding in oncology.
Opportunity ID: 351181
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-24-015 |
| Funding Opportunity Title: | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | |
| Expected Number of Awards: | |
| CFDA Number(s): | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 28, 2023 |
| Last Updated Date: | Nov 28, 2023 |
| Original Closing Date for Applications: | Oct 01, 2024 |
| Current Closing Date for Applications: | Oct 01, 2024 |
| Archive Date: | Nov 06, 2024 |
| Estimated Total Program Funding: | |
| Award Ceiling: | $150,000 |
| Award Floor: | $ |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments City or township governments Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Special district governments Public housing authorities/Indian housing authorities Small businesses Native American tribal governments (Federally recognized) Private institutions of higher education County governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications (formerly called “competing revisions”) from currently funded NCI P30 centers. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities. As a component of the NCI IMAT program, this NOFO aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-015.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact: NIH Grants Information
grantsinfo@nih.gov |